Enlivex Therapeutics (ENLV) Stock Price, News & Analysis

Company Overview

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system. Allocetra is currently being evaluated in clinical trials for indications such as sepsis, acute respiratory distress syndrome (ARDS), and cytokine storm associated with COVID-19. Enlivex’s pipeline also explores the potential of macrophage-based treatments to reduce complications in stem cell transplantation and support cancer therapies by mitigating treatment-related hyperinflammation.

Enlivex collaborates with academic medical centers and contract research organizations across North America and Europe to advance its clinical programs. The management team brings expertise in immunology, cell therapy manufacturing, and regulatory affairs, positioning the company to scale production and pursue global regulatory approvals. Enlivex continues to build strategic partnerships aimed at broadening access to its cell-based immunotherapies for patients facing severe inflammatory disorders.

Key Stats

• Today's Range: $1.02 to $1.16
• 50-Day Range: $1.10 to $8.70
• 52-Week Range: $1.02 to $27.15
• Volume: 251,053 shs
• Average Volume: 292,121 shs
• Market Capitalization: $19.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $247.50
• Consensus Rating: Moderate Buy

Enlivex Therapeutics Stock Analysis - MarketRank™

Enlivex Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 215th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Enlivex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Enlivex Therapeutics has a consensus price target of $247.50, representing about 22,400.0% upside from its current price of $1.10.

Amount of Analyst Coverage

Enlivex Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Enlivex Therapeutics are expected to grow in the coming year, from ($1.15) to ($0.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enlivex Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enlivex Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enlivex Therapeutics has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.68% of the float of Enlivex Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Enlivex Therapeutics has a short interest ratio ("days to cover") of 0.33, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enlivex Therapeutics has recently decreased by 41.31%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enlivex Therapeutics does not currently pay a dividend.

Dividend Growth

Enlivex Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: -0.12

News Sentiment

Enlivex Therapeutics has a news sentiment score of -0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Enlivex Therapeutics this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for ENLV on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

3 people have added Enlivex Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

1.02% of the stock of Enlivex Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 11/14/2025
• Today: 9/04/2026
• Next Earnings (Estimated): 9/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ENLV
• CIK: 1596812
• Web: www.enlivex.com
• Phone: (728) 662-3301
• Fax: 972-2620-8070
• Employees: 70
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Enlivex Therapeutics: $247.50
• High Price Target: $300.00
• Low Price Target: $195.00
• Potential Upside/Downside: +22,400.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $1.24 billion
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 248.08%
• Return on Assets: 206.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 193.24
• Quick Ratio: 193.24

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $122.21 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 17,490,000
• Free Float: 15,338,000
• Market Cap: $19.24 million
• Optionable: Optionable
• Beta: 1.42